(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Biftu, T., Feng, D., Qian, X., Liang, G.B., Kieczykowski, G., Eiermann, G., He, H., Leiting, B., Lyons, K., Petrov, A., Sinha-Roy, R., Zhang, B., Scapin, G., Patel, S., Gao, Y.D., Singh, S., Wu, J., Zhang, X., Thornberry, N.A., Weber, A.E.(2007) Bioorg Med Chem Lett 17: 49-52
- PubMed: 17055272 
- DOI: https://doi.org/10.1016/j.bmcl.2006.09.099
- Primary Citation of Related Structures:  
2IIT, 2IIV - PubMed Abstract: 
Replacement of the triazolopiperazine ring of sitagliptin (DPP-4 IC(50)=18nM) with 3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one gave dipeptidyl peptidase IV (DPP-4) inhibitor 1 which is potent (DPP-4 IC(50)=2.6nM), selective, and efficacious in an oral glucose tolerance test in mice. It was selected for extensive preclinical development as a potential back-up candidate to sitagliptin.
Organizational Affiliation: 
Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., PO Box 2000, Rahway, NJ 07065, USA. Tesfaye_Biftu@merck.com